NovoCure Limited

As of June 30, 2026, NovoCure Limited carries a market capitalization of 1.76B, placing it among publicly traded companies globally. Its enterprise value stands at 1.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NovoCure Limited's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, NovoCure Limited has 116.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.46, and the price-to-book ratio stands at 5.22.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.56B versus a market cap of 1.76B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NovoCure Limited maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, NovoCure Limited posted a negative return on equity (ROE) of -43.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -14.56, reflecting losses generated across the asset base. The company generates approximately 443,720.77 in revenue per employee across its workforce of 1,575.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.05 indicates how many times NovoCure Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, NovoCure Limited recorded an income tax benefit of -4.12M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -152.69M and -148.56M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, NovoCure Limited's stock has gained approximately 8.95% over the past 52 weeks. The 50-day moving average sits at 16.21, while the 200-day moving average is 14.82.

Over the twelve months ended June 30, 2026, NovoCure Limited generated 699.19M in revenue and converted that into -148.56M in net income, yielding earnings per share of -1.31. EBITDA reached -138.08M, while operating income came in at -154.40M.

As of June 30, 2026, NovoCure Limited holds 440.56M in cash and equivalents against 233.42M in total debt, resulting in a net debt position of 102.19M. Total book value stands at 338.09M, with working capital of 417.81M providing operational flexibility.

NovoCure Limited produced -2.81M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22.62M in capital expenditures, free cash flow totaled -25.43M - equivalent to -0.22 per share.

Over the twelve months ended June 30, 2026, NovoCure Limited posted a gross margin of 76.13, reflecting its pricing power and cost economics. The operating margin of -22.08 and net profit margin of -21.25 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 25.77, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NovoCure Limited shareholders.

As of June 30, 2026, NovoCure Limited has an Altman Z-Score of 0.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.